Axis-shield Share Discussion Threads

[hotfinance14] 01/7/2010 12:49

If its a dog why are you going to buy at 200p ? Woof Woof.

[slaterlp] 01/7/2010 11:08

Hold your powder, keep it dry. 200 coming to this stock soon.

Thats when I will take a punt.

But you have to say, looking at the shape of the chart, that resembles a cliff face, there has been a massive re-rating of this in the market.

I can't help but wonder if some VERY bad news is just around the corner on this dog.

[slaterlp] 01/7/2010 11:01

245 and going down !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

[cumnor] 29/6/2010 14:26

Salpara, the market it is in is a growing one, and their stage of development, diversity and some quite specific but common tests (incl the anti-ccp test and active B12) gives them an advantage I believe, despite pressures on healthcare budgets. In fact tests like active B12 and anti-ccp should be more in demand as doctors will be looking for more precise and quick diagnoses, considering the costs of investigating and treating patients with non specific symptoms. I think the directors of ASD are well tuned into prospects here. they did'nt buy too many shares at 4£ plus, and the healthcare market should show more resilience than housing cutbacks. imo dyor

[salpara111] 29/6/2010 10:01

cumnor,

director buys are no indication of future performance.
I remeber watching as Shagger Norris continued to buy shares in Jarvis, he was a non exec director (I am talking about the last time it was rescued a couple of years back)only to see it engage in a massive debt for equity swap almost totally wiping out the shareholders.
On a more current note, the new chairman of Conaught CNT bought £500,000 of shares in the company less than 8 weeks ago...now worth about £165,000....ouch!
I think that when you are so "invested" in the success of a company by being a director it is difficult to be dispassionate and objective. I am not being hard on the directors of ASD in particular, I think that it is a problem across the board.

[cumnor] 29/6/2010 09:40

Salpara, agree. Expectations always high here but director buys and options after profit warning in May suggests to me insiders believe company can still perform. I suspect, at this price, it will be taken-over soon. imo dyor

[salpara111] 29/6/2010 09:31

Problem here is that the company was always valued on the assumption of high growth ie p/e in excess of 25 and no dividend.
Now we are in a situation where revenue growth is flat at best (remember that if inflation in your markets averages 2% and your revenue grows by 2% then you are effectively going nowhere)
If you decide that the company is going to continue growing but at a much reduced rate then you will re-rate the company which means a much lower prospective p/e will be allowed and holders will be looking for dividends.
The good thing about having a decent dividend (which in todays market appears to be a minimum of 4.5%) is that it provides some support to your share price
The market is clearly disappointed with todays trading statement given the share price action so I will wait a while longer.
I still reckon there is a decent business here but until the re-rating is complete I will wait.

[damian] 29/6/2010 08:56

cumnor

Yes i agree ASD is a good buy at this share price v M/cap i am tucking a few away when i can.

[cumnor] 29/6/2010 08:36

These wily Scots! Bang in line with 'profit warning' in May. Revenue still up on last last year (rather than down) and own direct sales 6% up. If this is what happens in 'bad times' then I really look forward to the much anticipated 'turnaround'.

Funny how this coincided with new boy moving in and directors pile in to buy shares nearly £2 cheaper than they were before the ' profit warning'. And now suddenly a rake of new director and employee options issued at £2.52. So profit likely to still be up on last year, new very significant tests announced and placament of testing platforms going well in US. Read between the lines. Very happy with these and trading up-date exactly as I expected. Which is why I bougt in recently and might even top up if the mms oblige. I see it as a likely takeover target. And soon at this price. aimo dyor.

[nick100] 29/6/2010 07:11

Dundee, Scotland, 29 June 2010: Axis-Shield (LSE:ASD, OSE:ASD), the international in vitro diagnostics company, today issues the following pre-close update for the six months ending 30 June 2010, ahead of the Company's Interim Results announcement anticipated on 25 August 2010.



As outlined in our Interim Management Statement on 10th May, and in common with other companies reporting in the sector, a poor influenza season has impacted revenues for the first half of the year, affecting sales of Afinion™ and NycoCard® CRP. As also previously reported sales have been additionally affected by reduced demand for third party products due to budgetary pressures in the Nordic Region; and lower sales of HbA1c tests due to pressures on discretionary healthcare expenditure. After adjusting for sales connected with our Plasmatec subsidiary, which was sold in May last year, reported revenues are expected to show growth of around 2% in the first six months of 2010 compared to the same period in 2009. Excluding third party distributed products, growth is likely to be around 6%. In our Laboratory Division, we recently announced another important launch of our anti-CCP assay for early detection of rheumatoid arthritis by Technogenetics on the automated Zenit RA platform (distributed by Menarini in Europe) and the development of our HbA1c test for the Abbott Architect system is on track. We continue to focus on marketing our Afinion™ Point-of-Care analyser, particularly in the key US physicians' office market, and new system placements are proceeding well.

[slaterlp] 29/6/2010 02:22

look at the share price and the direction its taken over the years.

It says it all.

Sell and buy at 200 ish.

Loyalty to a stock is one thing but blind faith is crazy.

The good news is always overplayed, and finally an admission on profits has put the skids under this stock.

My logic is based on reality. its not 400 ish any more. there is NO POSSIBILTY of 600 in 2 years as the dreamers keep saying, and if it goes to a bid it wont be for much more than it is now.

Clearly if it was wanted and thought worth it, at this price there would be some action by a bidder. NONE.

SELL SELL SELL

[slaterlp] 29/6/2010 02:21

Come on hot, look at the share price and the direction its taken over the years.

It says it all.

Sell and buy at 200 ish.

Loyalty to a stock is one thing but blind faith is crazy.

The good news is always overplayed, and finally an admission on profits has put the skids under this stock.

My logic is based on reality. its not 400 ish any more. there is NO POSSIBILTY of 600 in 2 years as the dreamers keep saying, and if it goes to a bid it wont be for much more than it is now.

Clearly if it was wanted and thought worth it, at this price there would be some action by a bidder. NONE.

SELL SELL SELL

[hotfinance14] 26/6/2010 10:14

Whats your logic then slater ?

[slaterlp] 26/6/2010 01:35

Axis-Shield - NOT --- A 'profitable' and relatively low risk growth play.

This IS the CORRECT name for this thread. NOT THE TIRED OLD MISLEADING, AND FRANKLY LUDICROUS one that many of you read and comment on.


No, this is correct. Axis-Shield - NOT --- A 'profitable' and relatively low risk growth play.

It describes the company well. Especially after ASD's own admission of diminishing profits going forward.

Axis-Shield - NOT --- A 'profitable' and relatively low risk growth play
Axis-Shield - NOT --- A 'profitable' and relatively low risk growth play
Axis-Shield - NOT --- A 'profitable' and relatively low risk growth play.

Got that?

SELL SELLSELL SELLSELL SELLSELL SELLSELL SELLSELL SELLSELL SELL
SELL SELLSELL SELLSELL SELLSELL SELLSELL SELLSELL SELLSELL SELL
SELL SELLSELL SELLSELL SELLSELL SELLSELL SELLSELL SELLSELL SELL

Buy back at 200.

[slaterlp] 26/6/2010 01:31

Anybody buying into this stock until it reaches circa 200, is demented.

Dont say I didn't warn you.

Just as I did before, when the fools and rampers on here, were saying that at 400 or so, it was SOOOOOOOOOO cheap, and how they were adding for thier pensions.

I was right, they were wrong.

I am right now too.

SELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELLSELL

[damian] 25/6/2010 10:43

cumnor

I hope so as i am taking this weakness in the share price to build up a holding in ASD
for the long term in my ISA.

[cumnor] 25/6/2010 10:23

News on Govt funding of expensive arthritis drugs should be good for ASD. It will put more pressure on Doctors to be absolutely sure of a RA diagnosis prior to commencing very expensive long term tx. The anti-ccp test will be part of the mananagement imo.

[damian] 24/6/2010 13:42

I have bought back in as ASD seems cheap on fundies,Director buys were a positive.

Recent news is good though ASD through that bombshell that savaged the SP,i guess time will tell !.

[nick100] 23/6/2010 07:15

AXIS-SHIELD ANNOUNCES LAUNCH OF NEW ANTI-CCP TEST FOR
RHEUMATOID ARTHRITIS ON THE ZENIT RA ANALYSER

Dundee, Scotland, 23 June 2010: Axis-Shield plc (LSE:ASD, OSE:ASD), the
international in-vitro diagnostics (IVD) company, today announces the launch of
an automated anti-CCP test for the early detection of rheumatoid arthritis on
the new Zenit RA analyser system. The assay is based on Axis-Shield's
proprietary technology and measures antibodies against cyclic citrullinated
peptides (anti-CCP), a novel marker that has been shown to have superior
specificity in the diagnosis of rheumatoid arthritis. The assay and system are
being launched by Technogenetics of Italy (part of the Bouty Healthcare Group),
through an exclusive European distribution agreement with Menarini, and will be
available for sale outside the USA.

Anti-CCP testing is one of the fastest growing markets in laboratory diagnostics
as its utility in the diagnosis of early rheumatoid disease becomes increasingly
recognized.

Ian Gilham, Axis-Shield CEO, commented: "This is another important milestone in
the commercial development of our anti-CCP test. We await final confirmation
that the measurement of these antibodies will be included by the American
College of Rheumatology as a key parameter in the diagnosis of rheumatoid
arthritis, after which we anticipate further expansion of this important
market."

[brucie5] 22/6/2010 09:58

slaterlp: I think you've been holding your breath too long.
(No wonder you're dreaming.)

[slaterlp] 22/6/2010 09:54

Dreeeeeeeeeeeeeeeeeeeeeeeam dream dream dream. la la la.

Dont hold your breath chaps. Its a dog, its ASD.


Look at the chart for heavens sake, it didn't fall out of fashion, IT FELL OFF A CLIFF!!!!!!!!!!!!!!!!!!!!!!!!!

This was no slow gradual decline, its a collapse. And there is more to come.

stop kidding yourselves and others.

Or are you trying to ramp it up to get your money back?

[cumnor] 21/6/2010 09:17

This company is value at this price. Would'nt be surprised to see Abbott take them out sometime. Added more this morning. imo

[brucie5] 19/6/2010 13:40

Very similar chart features to BVC; both have been around for more than 10 years, and swung in and out of fashion. Both small 'growth' shares, which then get severely punished when they disappoint that characterisation. I'm curious as to why the share price has not hit support at 2.50, which is the 08/9 low. It may well be forming a new (higher) base. It'll be back up in due course, but worth watching who's buying, and how much.

[salpara111] 19/6/2010 11:22

Seems to be stabilising, I am going to set a limit order at 260 and see if it gets filled next week.
The company is now cheap enough that they could become a bolt on acquisition for one of the bigger medical devices companies.
It is all about risk/reward profile and I guess I see more potential reward at current levels than risk.

[brucie5] 18/6/2010 18:49

What rubbish. Chart suggests this is well worth watching. 4th rising low from 2007. Business model is sound enough. Affinion is a great product. Ups and downs are power for the course: look at VEC or BTG. And profit by their example.

I'm not in; but certainly interested, as a long term watcher of this company.